CLINICAL TRIAL: NCT00856765
Study Title: Randomized Comparison of Drug Eluting Balloon/Bare Metal Stent Versus Drug Eluting Stent Versus Bare Metal Stent for the Treatment of Patients With Acute ST-elevation Myocardial Infarction
Keyword	NOT FOUND
Lead sponsor: Other; UMC Utrecht
Intervention MeSH	NOT FOUND
Condition MeSH:Atherosclerosis; Coronary Artery Disease; Myocardial Ischemia; Coronary Disease; Infarction; Myocardial Infarction; Thrombosis
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01322009
Study Title: Overcoming Membrane Transporters to Improve CNS Drug Delivery
Drug ref found!
intervention_type	Drug
arm_group_label	Drug
description	After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days or to receive placebos.
intervention_name	Probenecid and N-acetyl cysteine
other_name	Ora Plus
intervention_type	Drug
arm_group_label	Placebo
description	After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days. Placebo contents include equal volumes and dosing regimens of lactose powder (for opacity) suspended in Ora-Plus and normal saline.
intervention_name	Placebo
Drug ref found!
intervention_type	Drug
arm_group_label	Drug
description	After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days or to receive placebos.
intervention_name	Probenecid and N-acetyl cysteine
other_name	Ora Plus
intervention_type	Drug
arm_group_label	Placebo
description	After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days. Placebo contents include equal volumes and dosing regimens of lactose powder (for opacity) suspended in Ora-Plus and normal saline.
intervention_name	Placebo
Keywords:Children; Brain injury; Trauma
Lead sponsor: Other; University of Pittsburgh
Collaborator: NIH; National Institutes of Health (NIH)
Collaborator: NIH; National Institute of Neurological Disorders and Stroke (NINDS)
Intervention MeSH:Acetylcysteine; N-monoacetylcystine; Probenecid
Condition MeSH:Brain Injuries
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01372254
Study Title: Behavioral Intervention for Low Income Depressed Smokers in Drug Treatment
Drug ref found!
other_name	ST
intervention_type	Behavioral
arm_group_label	Standard smoking cessation treatment (ST)
description	Participants will receive a standard, individual smoking cessation treatment, based on the most recent clinical practice guideline for treating tobacco use from the U.S. Department of Health and Human Services. Treatment will be delivered in 5, 90-minute group sessions over an 4-5 week period. Patients in ST will also keep a weekly written journal throughout treatment elaborating on observations about the day's events, their thoughts, feelings, and insights about their reactions to these events as a means to equate for time spent on daily activity monitoring in the BAD-AS condition.
intervention_name	Standard Treatment
other_name	BAD-AS
intervention_type	Behavioral
arm_group_label	Behavioral Activation for Substance Abusing Smokers (BA-DAS)
description	BAD-AS is focused on identifying life areas, values, and daily activities to help one live according to his or her values. Treatment will be delivered in 5, 90-minute individual sessions over a 4-5 week period.
intervention_name	BAD-AS
other_name	Nicoderm CQ
intervention_type	Drug
arm_group_label	Standard smoking cessation treatment (ST)
arm_group_label	Behavioral Activation for Substance Abusing Smokers (BA-DAS)

description	8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant's initial nicotine level.
intervention_name	Transdermal Nicotine Patch
Keywords:Cigarette Smoking; Drug Use; Depressed Mood
Lead sponsor: Other; University of Maryland
Collaborator: Other; American Cancer Society, Inc.
Intervention MeSH:Nicotine; Nicotine polacrilex
Condition MeSH:Smoking; Depression
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01090505
Study Title: Phase 2 Study of S-1 and Oxaliplatin as Neoadjuvant Chemotherapy for Locally Advanced
other_name	S-1:Taiho
other_name	Oxaliplatinï¼šsanofi-aventis

intervention_type	Drug
arm_group_label	Drug:S-1:80mg/m2;oxaliplatin 130mg/m2
arm_group_label	surgery

description	Drug:S-1:80mg/m2;oxaliplatin 130mg/m2
intervention_name	Drug: S-1 and  oxaliplatin
Keyword	NOT FOUND
Lead sponsor: Other; Chinese PLA General Hospital
Intervention MeSH:Oxaliplatin
Condition MeSH:Stomach Neoplasms
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01268215
Study Title: The Effect of Endotracheal Instillation of Surfactant With and Without Budesonide on the Development of Bronchopulmonary Dysplasia in Ventilator-dependent, Extremely Low Birth Weight Infants: A Pilot Study
Drug ref found!
other_name	Calfactant
intervention_type	Drug
arm_group_label	A (two study drugs group)
arm_group_label	B (one study drug group)

description	Endotracheal instillation of Infasurf once per week for three weeks
intervention_name	Infasurf
other_name	Budesonide
intervention_type	Drug
arm_group_label	A (two study drugs group)
description	Endotracheal instillation, once per week for three weeks
intervention_name	Pulmicort
other_name	Air Sham
intervention_type	Other
arm_group_label	C (no study drug group)
description	None instilled through the endotracheal tube
intervention_name	Sham
Drug ref found!
other_name	Calfactant
intervention_type	Drug
arm_group_label	A (two study drugs group)
arm_group_label	B (one study drug group)

description	Endotracheal instillation of Infasurf once per week for three weeks
intervention_name	Infasurf
other_name	Budesonide
intervention_type	Drug
arm_group_label	A (two study drugs group)
description	Endotracheal instillation, once per week for three weeks
intervention_name	Pulmicort
other_name	Air Sham
intervention_type	Other
arm_group_label	C (no study drug group)
description	None instilled through the endotracheal tube
intervention_name	Sham
Keywords:Bronchopulmonary Dysplasia; Budesonide; Infasurf
Lead sponsor: Other; East Carolina University
Intervention MeSH:Budesonide; Calfactant
Condition MeSH:Bronchopulmonary Dysplasia
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01199575
Study Title: A Two-Arm, Multi-center Trial of Revlimid® and Rituximab, for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Drug ref found!
other_name	Chronic Lymphocytic Leukemia
other_name	Relapsed
other_name	Refractory
other_name	Revlimid(lenalidomide)
other_name	Rituximab (rituxan)

intervention_type	Drug
arm_group_label	A: Subjects younger than 65 years old.
description	Drug:Lenalidomide and Rituximab Revlimid starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of Revlimid monotherapy, continued weekly throughout cycle 2, and then every monthly for subsequent cycles.Patients with residual disease, but without evidence of significant toxicity or progressive disease may stay on study for up to 6 additional cycles of single agent Revlimid. Each patient may receive up to a maximum of 13 cycles of treatment if no progressive disease or significant toxicity.
intervention_name	Revlimid, rituximab
other_name	Chronic Lymphocytic Leukemia
other_name	Relapsed
other_name	Refractory
other_name	Revlimid(lenalidomide)
other_name	Rituximab (rituxan)

intervention_type	Drug
arm_group_label	B: Subjects age 65 years and older
description	Drug:Lenalidomide and Rituximab Revlimid starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of Revlimid monotherapy, continued weekly throughout cycle 2, and then every monthly for subsequent cycles.Patients with residual disease, but without evidence of significant toxicity or progressive disease may stay on study for up to 6 additional cycles of single agent Revlimid. Each patient may receive up to a maximum of 13 cycles of treatment if no progressive disease or significant toxicity.
intervention_name	Relapsed or refractory CLL. Lenalidomide and Rituximab
Drug ref found!
other_name	Chronic Lymphocytic Leukemia
other_name	Relapsed
other_name	Refractory
other_name	Revlimid(lenalidomide)
other_name	Rituximab (rituxan)

intervention_type	Drug
arm_group_label	A: Subjects younger than 65 years old.
description	Drug:Lenalidomide and Rituximab Revlimid starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of Revlimid monotherapy, continued weekly throughout cycle 2, and then every monthly for subsequent cycles.Patients with residual disease, but without evidence of significant toxicity or progressive disease may stay on study for up to 6 additional cycles of single agent Revlimid. Each patient may receive up to a maximum of 13 cycles of treatment if no progressive disease or significant toxicity.
intervention_name	Revlimid, rituximab
other_name	Chronic Lymphocytic Leukemia
other_name	Relapsed
other_name	Refractory
other_name	Revlimid(lenalidomide)
other_name	Rituximab (rituxan)

intervention_type	Drug
arm_group_label	B: Subjects age 65 years and older
description	Drug:Lenalidomide and Rituximab Revlimid starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of Revlimid monotherapy, continued weekly throughout cycle 2, and then every monthly for subsequent cycles.Patients with residual disease, but without evidence of significant toxicity or progressive disease may stay on study for up to 6 additional cycles of single agent Revlimid. Each patient may receive up to a maximum of 13 cycles of treatment if no progressive disease or significant toxicity.
intervention_name	Relapsed or refractory CLL. Lenalidomide and Rituximab
Keywords:Chronic Lymphocytic Leukemia; CLL; Relapsed or Refractory; previously treated
Lead sponsor: Other; Chronic Lymphocytic Leukemia Research Consortium
Collaborator: Industry; Celgene Corporation
Intervention MeSH:Rituximab; Thalidomide; Lenalidomide
Condition MeSH:Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01246557
Study Title: Open Label Multi-center Pilot Phase I/II Non-controlled Clinical Trial to Assess Safety and Efficieecy of the Lenalidomide and Dexamethasone Association in Patients With Chronic Relapse or Treatment Resistant Lymphatic Leukemia Following Treatment Containing Fludarabine.
Drug ref found!
other_name	REVLIMID®
intervention_type	Drug
description	Lenalidomide - RevlimidÂ®: an analogue of thalidomide, is an immunomodulator agent with anti-angiogenic properties. The chemical name is 3-(4 Ì-aminoisoindoline-1 Ìona)-1- piperidine-2,6-dione.
REVLIMIDÂ® (lenalidomide) is available in capsules of 5 mg, 10 mg and 15 mg p.o.. Each capsule contains lenalidomide as active ingredient and the following non active ingredients: anhydrous lactose, microcrystalline cellulose, sodium croscarmellose and magnesium stearate.
intervention_name	Lenalidomide
other_name	Commercial drug according to standard clinical practices of the center.
intervention_type	Drug
description	Dexamethasone will be administered as 20 mg/day (on days 1 to 4) for oral administration.
intervention_name	Dexamethasone
Drug ref found!
other_name	REVLIMID®
intervention_type	Drug
description	Lenalidomide - RevlimidÂ®: an analogue of thalidomide, is an immunomodulator agent with anti-angiogenic properties. The chemical name is 3-(4 Ì-aminoisoindoline-1 Ìona)-1- piperidine-2,6-dione.
REVLIMIDÂ® (lenalidomide) is available in capsules of 5 mg, 10 mg and 15 mg p.o.. Each capsule contains lenalidomide as active ingredient and the following non active ingredients: anhydrous lactose, microcrystalline cellulose, sodium croscarmellose and magnesium stearate.
intervention_name	Lenalidomide
other_name	Commercial drug according to standard clinical practices of the center.
intervention_type	Drug
description	Dexamethasone will be administered as 20 mg/day (on days 1 to 4) for oral administration.
intervention_name	Dexamethasone
Keyword:Patients with Chronic Lymphatic Leukemia relapsing or resistant to treatment
Lead sponsor: Other; Hospital Universitari Vall d'Hebron Research Institute
Intervention MeSH:Dexamethasone acetate; Dexamethasone; Dexamethasone 21-phosphate; Lenalidomide; Thalidomide; BB 1101
Condition MeSH:Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01278004
Study Title: A Randomised Double-blind Placebo-controlled Trial of the Safety and Efficacy of Ethosuximide 250mg Capsules for the Management of Chemotherapy Induced Painful Peripheral Neuropathy
Drug ref found!
intervention_type	Drug
arm_group_label	Drug
description	Drug will be dose escalated in order to reach maximum tolerated dose starting with 250mg.
intervention_name	Ethosuximide
intervention_type	Drug
arm_group_label	Placebo
description	Capsule
intervention_name	Placebo
Drug ref found!
intervention_type	Drug
arm_group_label	Drug
description	Drug will be dose escalated in order to reach maximum tolerated dose starting with 250mg.
intervention_name	Ethosuximide
intervention_type	Drug
arm_group_label	Placebo
description	Capsule
intervention_name	Placebo
Keyword:Adult cancer patients with chemotherapy-induced painful peripheral neuropathy
Lead sponsor: Other; Royal Marsden NHS Foundation Trust
Collaborator: Other; Imperial College London
Intervention MeSH:Ethosuximide
Condition MeSH:Peripheral Nervous System Diseases; Demyelinating Diseases; Polyneuropathies; Nerve Compression Syndromes; Neurologic Manifestations; Neurotoxicity Syndromes
### END TRIAL DATA ###

CLINICAL TRIAL: NCT00852228
Study Title: Optimal Control of Liver Metastases With Intravenous Cetuximab and Hepatic Artery Infusion of Three-drug Chemotherapy in Patients With Liver-only Metastases From Colorectal Cancer. A European Multicenter Phase II Trial
Drug ref found!
other_name	Erbitux
intervention_type	Drug
arm_group_label	chronomodulated HAI chemotherapy
arm_group_label	conventional HAI chemotherapy

description	Cetuximab is administered every two weeks at the dose of 500 mg/m² over 2h30 (150 minutes).
intervention_name	IV cetuximab
other_name	Campto
other_name	Eloxatin

intervention_type	Drug
arm_group_label	chronomodulated HAI chemotherapy
description	Irinotecan (180 mg/m²) on day 2 as a 6 hour infusion, starting at 2:00, with a peak at 5:00
Oxaliplatin (85 mg/m²) in split daily doses for 3 days, starting on day 2. Daily sinusoidal infusion duration will last from 10:15 to 21:45, with peak delivery rate at 16:00.
5-Fluorouracil (2800 mg/m²) in split daily doses for 3 days, alternating with oxaliplatin infusions, starting on day 2. Daily sinusoidal infusions will last from 22:15 to 9:45 , with peak delivery at 4:00.
Treatments will be repeated every 2 weeks.
intervention_name	HAI chronomodulated chemotherapy
other_name	Campto
other_name	Eloxatin

intervention_type	Drug
arm_group_label	conventional HAI chemotherapy
description	Irinotecan (180 mg/m²) on day 1 as a one hour infusion, then
Oxaliplatin (85 mg/m²) on day 1 as a two hour infusion, then
5-Fluorouracil (2800 mg/m²) as a 48 h infusion starting on day 2, after completion of oxaliplatin delivery.
Treatments will be repeated every 2 weeks.
intervention_name	HAI conventional chemotherapy
Drug ref found!
other_name	Erbitux
intervention_type	Drug
arm_group_label	chronomodulated HAI chemotherapy
arm_group_label	conventional HAI chemotherapy

description	Cetuximab is administered every two weeks at the dose of 500 mg/m² over 2h30 (150 minutes).
intervention_name	IV cetuximab
other_name	Campto
other_name	Eloxatin

intervention_type	Drug
arm_group_label	chronomodulated HAI chemotherapy
description	Irinotecan (180 mg/m²) on day 2 as a 6 hour infusion, starting at 2:00, with a peak at 5:00
Oxaliplatin (85 mg/m²) in split daily doses for 3 days, starting on day 2. Daily sinusoidal infusion duration will last from 10:15 to 21:45, with peak delivery rate at 16:00.
5-Fluorouracil (2800 mg/m²) in split daily doses for 3 days, alternating with oxaliplatin infusions, starting on day 2. Daily sinusoidal infusions will last from 22:15 to 9:45 , with peak delivery at 4:00.
Treatments will be repeated every 2 weeks.
intervention_name	HAI chronomodulated chemotherapy
other_name	Campto
other_name	Eloxatin

intervention_type	Drug
arm_group_label	conventional HAI chemotherapy
description	Irinotecan (180 mg/m²) on day 1 as a one hour infusion, then
Oxaliplatin (85 mg/m²) on day 1 as a two hour infusion, then
5-Fluorouracil (2800 mg/m²) as a 48 h infusion starting on day 2, after completion of oxaliplatin delivery.
Treatments will be repeated every 2 weeks.
intervention_name	HAI conventional chemotherapy
Drug ref found!
other_name	Erbitux
intervention_type	Drug
arm_group_label	chronomodulated HAI chemotherapy
arm_group_label	conventional HAI chemotherapy

description	Cetuximab is administered every two weeks at the dose of 500 mg/m² over 2h30 (150 minutes).
intervention_name	IV cetuximab
other_name	Campto
other_name	Eloxatin

intervention_type	Drug
arm_group_label	chronomodulated HAI chemotherapy
description	Irinotecan (180 mg/m²) on day 2 as a 6 hour infusion, starting at 2:00, with a peak at 5:00
Oxaliplatin (85 mg/m²) in split daily doses for 3 days, starting on day 2. Daily sinusoidal infusion duration will last from 10:15 to 21:45, with peak delivery rate at 16:00.
5-Fluorouracil (2800 mg/m²) in split daily doses for 3 days, alternating with oxaliplatin infusions, starting on day 2. Daily sinusoidal infusions will last from 22:15 to 9:45 , with peak delivery at 4:00.
Treatments will be repeated every 2 weeks.
intervention_name	HAI chronomodulated chemotherapy
other_name	Campto
other_name	Eloxatin

intervention_type	Drug
arm_group_label	conventional HAI chemotherapy
description	Irinotecan (180 mg/m²) on day 1 as a one hour infusion, then
Oxaliplatin (85 mg/m²) on day 1 as a two hour infusion, then
5-Fluorouracil (2800 mg/m²) as a 48 h infusion starting on day 2, after completion of oxaliplatin delivery.
Treatments will be repeated every 2 weeks.
intervention_name	HAI conventional chemotherapy
Keywords:colorectal cancer; unresectable metastases; neo-adjuvant chemotherapy; liver metastases; chronotherapy; cetuximab; irinotecan; oxaliplatin; 5-fluorouracil; hepatic artery infusion; Unresectable hepatic lesions; 1 to 3 prior chemotherapy regimens
Lead sponsor: Other; Association pour la Recherche sur le Temps Biologique et la Chronothérapie
Collaborator: Other; Gustave Roussy, Cancer Campus, Grand Paris
Collaborator: Industry; Merck Serono International SA
Collaborator: Industry; Pfizer
Collaborator: Other; CRESGE
Intervention MeSH:Fluorouracil; Oxaliplatin; Cetuximab
Condition MeSH:Colorectal Neoplasms; Neoplasm Metastasis; Neoplasms, Second Primary; Liver Neoplasms
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01455246
Study Title: Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis: an Open, Randomized, Controlled Clinical Trial
Drug ref found!
intervention_type	Drug
arm_group_label	Daptomycin + Meropenem
description	Daptomycin will be administered at the dose of 6 mg/kg every 24 hours and 6 mg/kg every 48 hours for an estimated creatinine clearance (CKD-EPI) of > 30 ml/min and < 30 ml/min respectively. Meropenem will be administered at the dose of 1 g t.i.d., 1 g b.i.d., 0.5 g every 24 hours for an estimated creatinine clearance of >50  ml/min, 10-50 ml/min, and < 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours will be added a rescue therapy with fluconazole. In patients in which cultures shown a bacterial species resistant to therapy, daptomycin and meropenem will be discontinued and replaced by a therapy based on antibiotic susceptibility of isolated species.
intervention_name	Daptomycin + Meropenem
intervention_type	Drug
arm_group_label	Ceftazidime
description	Ceftazidime will be administered at the dose of 2 g t.i.d, 2 g b.i.d and 2 g at every 24 hours  by intravenous infusion for an estimated creatinine clearance (CKD-EPI) of >50  ml/min, 10-50 ml/min, and < 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours, or in which cultures shown a bacterial species resistant to therapy, ceftazidime will be discontinued and replaced by a rescue therapy with meropenem and daptomycin as provided for the experimental arm
intervention_name	Ceftazidime
Drug ref found!
intervention_type	Drug
arm_group_label	Daptomycin + Meropenem
description	Daptomycin will be administered at the dose of 6 mg/kg every 24 hours and 6 mg/kg every 48 hours for an estimated creatinine clearance (CKD-EPI) of > 30 ml/min and < 30 ml/min respectively. Meropenem will be administered at the dose of 1 g t.i.d., 1 g b.i.d., 0.5 g every 24 hours for an estimated creatinine clearance of >50  ml/min, 10-50 ml/min, and < 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours will be added a rescue therapy with fluconazole. In patients in which cultures shown a bacterial species resistant to therapy, daptomycin and meropenem will be discontinued and replaced by a therapy based on antibiotic susceptibility of isolated species.
intervention_name	Daptomycin + Meropenem
intervention_type	Drug
arm_group_label	Ceftazidime
description	Ceftazidime will be administered at the dose of 2 g t.i.d, 2 g b.i.d and 2 g at every 24 hours  by intravenous infusion for an estimated creatinine clearance (CKD-EPI) of >50  ml/min, 10-50 ml/min, and < 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours, or in which cultures shown a bacterial species resistant to therapy, ceftazidime will be discontinued and replaced by a rescue therapy with meropenem and daptomycin as provided for the experimental arm
intervention_name	Ceftazidime
Keywords:Cirrhosis; Nosocomial Spontaneous Bacterial Peritonitis; Ascites; Daptomycin; Meropenem; Ceftazidime; Nosocomial infection; Multi drug resistant bacteria; Sepsis; Albumin
Lead sponsor: Other; University of Padova
Intervention MeSH:Ceftazidime; Daptomycin; Meropenem
Condition MeSH:Ascites; Liver Cirrhosis; Fibrosis; Peritonitis
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01503346
Study Title: Taking Herbal Formulaï¼šDaHuang GangTsao Tang to Improve the Appetite Loss Condition of Cancer Patients in Late-stageï¼šA Clinical Control Trial Study
other_name	Herbal Medicine Group
intervention_type	Drug
arm_group_label	herbal medicine
description	Intervention group
2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed and separated into four packages;
each package was given to each patient four times a day (three time after meal and one time before sleep);
each patient received the usual medication of the hospice ward at the same time;
record the patients' score of pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day;
record the patients' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at the 1st day and the 6th day.
intervention_name	DaHuang GanTsao Tang
Keyword:Appetite Loss
Lead sponsor: Other; Yu-De Liu
Collaborator: Other; Changhua Christian Hospital
Intervention MeSH	NOT FOUND
Condition MeSH:Anorexia
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01319422
Study Title: Clinical and Pharmacodynamic Comparison of Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
other_name	CC-4047
intervention_type	Drug
arm_group_label	Pomalidomide 2 mg/d days 1-28 of a 28 day cycle
arm_group_label	Pomalidomide 4 mg/d days 1-21 of a 28 day cycle

description	Comparison of different dosages and schedules of drug
intervention_name	Pomalidomide
Keywords:myeloma; multiple myeloma; pomalidomide; immunomodulatory
Lead sponsor: Other; Yale University
Collaborator: Industry; Celgene Corporation
Intervention MeSH:Thalidomide
Condition MeSH:Multiple Myeloma; Neoplasms, Plasma Cell
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01327586
Study Title: Abstinence-Linked Money Management Multisite
Keywords:disability; substance abuse; cocaine abuse; dual diagnosis; representative payee; HIV risk reduction
Lead sponsor: Other; Yale University
Collaborator: NIH; National Institute on Drug Abuse (NIDA)
Intervention MeSH	NOT FOUND
Condition MeSH:Cocaine-Related Disorders; Substance-Related Disorders
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01413035
Study Title: Safety/Efficacy Assessed Study on Transplantation Therapy Using Human Umbilical Cord/Placenta-derived Mesenchymal Stem Cells for Type 2 Diabetes Mellitus
Keywords:Diabetes; Diabetes Medicines: Oral Hypoglycemic Drugs and Insulins.; Umbilical Cord/placenta-Derived MSC; Transplantation
Lead sponsor: Other; Shandong University
Intervention MeSH:Insulin; Hypoglycemic Agents
Condition MeSH:Diabetes Mellitus; Diabetes Mellitus, Type 2
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01015352
Study Title: A Phase II Study of Azacitidine (Vidaza®) Combined to Epoetin Beta (NeoRecormon®) in IPSS Low-risk and Intermediate-1 MDS Patients, Resistant to ESA
Drug ref found!
other_name	Vidaza®
intervention_type	Drug
arm_group_label	Arm A
arm_group_label	Arm B

description	Azacitidine 75mg/sqm SQ per day for 5 days every 28 days
intervention_name	Azacitidine
other_name	Epoetin beta : 60000U weekly SQ injections
intervention_type	Drug
arm_group_label	Arm B
description	Epoetin beta : 60000U weekly SQ injections
NeoRecormon®
intervention_name	Epoetin beta
Drug ref found!
other_name	Vidaza®
intervention_type	Drug
arm_group_label	Arm A
arm_group_label	Arm B

description	Azacitidine 75mg/sqm SQ per day for 5 days every 28 days
intervention_name	Azacitidine
other_name	Epoetin beta : 60000U weekly SQ injections
intervention_type	Drug
arm_group_label	Arm B
description	Epoetin beta : 60000U weekly SQ injections
NeoRecormon®
intervention_name	Epoetin beta
Keyword:Myelodysplastic Syndromes
Lead sponsor: Other; Groupe Francophone des Myelodysplasies
Collaborator: Industry; Celgene Corporation
Collaborator: Industry; Roche Pharma AG
Intervention MeSH:Azacitidine; Epoetin Alfa
Condition MeSH:Myelodysplastic Syndromes; Preleukemia
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01432080
Study Title: Does Increasing Immunosuppression Prevent Transplant-associated Lung-disease Triggered by Viral Respiratory Tract Infection Following Allogeneic Stem Cell Transplant? A Pilot Study
Drug ref found!
other_name	Deltasone
other_name	Steroids

intervention_type	Drug
arm_group_label	SAMS
description	Prednisone 0.75 mg/kg actual body weight/day PO for 7 days followed by a 7 day taper.
intervention_name	Prednisone
intervention_type	Drug
arm_group_label	SAMS
description	Azithromycin 250 mg PO daily for 2 weeks, then 3 times per week until 3 months
intervention_name	Azithromycin
other_name	Singulair
intervention_type	Drug
arm_group_label	SAMS
description	Montelukast 10 mg PO qhs for 3 months
intervention_name	Montelukast
other_name	Budesonide
other_name	Formoterol

intervention_type	Drug
arm_group_label	SAMS
description	Symbicort 200/6 mcg, 2 inhalations every 12 hours for 3 months
intervention_name	Symbicort
Drug ref found!
other_name	Deltasone
other_name	Steroids

intervention_type	Drug
arm_group_label	SAMS
description	Prednisone 0.75 mg/kg actual body weight/day PO for 7 days followed by a 7 day taper.
intervention_name	Prednisone
intervention_type	Drug
arm_group_label	SAMS
description	Azithromycin 250 mg PO daily for 2 weeks, then 3 times per week until 3 months
intervention_name	Azithromycin
other_name	Singulair
intervention_type	Drug
arm_group_label	SAMS
description	Montelukast 10 mg PO qhs for 3 months
intervention_name	Montelukast
other_name	Budesonide
other_name	Formoterol

intervention_type	Drug
arm_group_label	SAMS
description	Symbicort 200/6 mcg, 2 inhalations every 12 hours for 3 months
intervention_name	Symbicort
Drug ref found!
other_name	Deltasone
other_name	Steroids

intervention_type	Drug
arm_group_label	SAMS
description	Prednisone 0.75 mg/kg actual body weight/day PO for 7 days followed by a 7 day taper.
intervention_name	Prednisone
intervention_type	Drug
arm_group_label	SAMS
description	Azithromycin 250 mg PO daily for 2 weeks, then 3 times per week until 3 months
intervention_name	Azithromycin
other_name	Singulair
intervention_type	Drug
arm_group_label	SAMS
description	Montelukast 10 mg PO qhs for 3 months
intervention_name	Montelukast
other_name	Budesonide
other_name	Formoterol

intervention_type	Drug
arm_group_label	SAMS
description	Symbicort 200/6 mcg, 2 inhalations every 12 hours for 3 months
intervention_name	Symbicort
Drug ref found!
other_name	Deltasone
other_name	Steroids

intervention_type	Drug
arm_group_label	SAMS
description	Prednisone 0.75 mg/kg actual body weight/day PO for 7 days followed by a 7 day taper.
intervention_name	Prednisone
intervention_type	Drug
arm_group_label	SAMS
description	Azithromycin 250 mg PO daily for 2 weeks, then 3 times per week until 3 months
intervention_name	Azithromycin
other_name	Singulair
intervention_type	Drug
arm_group_label	SAMS
description	Montelukast 10 mg PO qhs for 3 months
intervention_name	Montelukast
other_name	Budesonide
other_name	Formoterol

intervention_type	Drug
arm_group_label	SAMS
description	Symbicort 200/6 mcg, 2 inhalations every 12 hours for 3 months
intervention_name	Symbicort
Keywords:Pulmonary disease, chronic obstructive; Viral respiratory tract infections; Respiratory syncytial viruses; Influenza virus A; Influenza virus B; Transplantation, Allogeneic
Lead sponsor: Other; Maisonneuve-Rosemont Hospital
Collaborator: Other; The Canadian Blood and Marrow Transplant Group
Intervention MeSH:Prednisone; Montelukast; Azithromycin; Symbicort
Condition MeSH:Bronchiolitis; Bronchiolitis Obliterans; Lung Diseases; Pneumonia; Respiratory Tract Infections; Lung Diseases, Interstitial; Cryptogenic Organizing Pneumonia
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01058395
Study Title: Phase I Study of Minocycline in a Dose Escalation Study as a Safe, Efficacious Therapeutic Intervention for Moderate and Severe TBI in Humans
intervention_type	Drug
arm_group_label	800 mg loading followed by 200 mg Q12
arm_group_label	800 mg loading followed by 400 mg Q12

description	Minocycline will be delivered in an open-label randomized study for seven days intravenously in one of two different dosing tiers to assess safety and toxicity per FDA recommendations. There will be tow different arms or groups differing by the amount of minocycline given over 7 days.
intervention_name	Minocycline
Keywords:Traumatic Brain Injury; Minocycline; Outcome
Lead sponsor: Other; Wayne State University
Intervention MeSH:Minocycline
Condition MeSH:Brain Injuries
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01385553
Study Title: Randomized Trial of Fathers for Change: An Intervention for Fathers With Co-Occuring Domestic Violence and Substance Abuse
Keyword	NOT FOUND
Lead sponsor: Other; Yale University
Collaborator: NIH; National Institute on Drug Abuse (NIDA)
Intervention MeSH	NOT FOUND
Condition MeSH:Substance-Related Disorders
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01489228
Study Title: Phase 2 Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Three Oral E1224 Dosing Regimens and Benznidazole for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease
Drug ref found!
other_name	E1224 (prodrug for active ingredient Ravuconazole)
intervention_type	Drug
arm_group_label	High Dose E1224
arm_group_label	Low Dose E1224
arm_group_label	Short Dose E1224

description	100 mg tablets
intervention_name	E1224
other_name	Benznidazole (N-benzil-2-nitro-1-imidazolacetamida)
intervention_type	Drug
arm_group_label	Benznidazol
description	100mg tablets
intervention_name	Benznidazole
intervention_type	Drug
arm_group_label	Placebo
description	tablets
intervention_name	Placebo
Drug ref found!
other_name	E1224 (prodrug for active ingredient Ravuconazole)
intervention_type	Drug
arm_group_label	High Dose E1224
arm_group_label	Low Dose E1224
arm_group_label	Short Dose E1224

description	100 mg tablets
intervention_name	E1224
other_name	Benznidazole (N-benzil-2-nitro-1-imidazolacetamida)
intervention_type	Drug
arm_group_label	Benznidazol
description	100mg tablets
intervention_name	Benznidazole
intervention_type	Drug
arm_group_label	Placebo
description	tablets
intervention_name	Placebo
Drug ref found!
other_name	E1224 (prodrug for active ingredient Ravuconazole)
intervention_type	Drug
arm_group_label	High Dose E1224
arm_group_label	Low Dose E1224
arm_group_label	Short Dose E1224

description	100 mg tablets
intervention_name	E1224
other_name	Benznidazole (N-benzil-2-nitro-1-imidazolacetamida)
intervention_type	Drug
arm_group_label	Benznidazol
description	100mg tablets
intervention_name	Benznidazole
intervention_type	Drug
arm_group_label	Placebo
description	tablets
intervention_name	Placebo
Keyword:Chagas Disease
Lead sponsor: Other; Drugs for Neglected Diseases
Collaborator: Industry; Eisai Co., Ltd.
Intervention MeSH:Benzonidazole
Condition MeSH:Chagas Disease
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01507103
Study Title: A Multi-center, Randomized, Open-label, Mechanism of Action Trial on the Biological Effects of the Therapeutic Cancer Vaccine Stimuvax® (L-BLP25) in Rectal Cancer Subjects Undergoing Neoadjuvant Chemoradiotherapy
Drug ref found!
intervention_type	Other
arm_group_label	Chemoradiation Therapy, L-BLP25 with Cyclophosphamide
description	Radiotherapy: 45-52 grays (Gy) applied for five weeks. Oral capecitabine (825 mg/m² twice daily) or 5FU, started at the first day of radiotherapy and given 5-7 days per week during the time of radiotherapy.
intervention_name	Chemoradiation Therapy
intervention_type	Drug
arm_group_label	Chemoradiation Therapy, L-BLP25 with Cyclophosphamide
description	Cyclophosphamide (day-3) 300 mg/m²
intervention_name	Cyclophosphamide
intervention_type	Biological
arm_group_label	Chemoradiation Therapy, L-BLP25 with Cyclophosphamide
description	L-BLP25 806 µg per vaccination once weekly for 8 weeks (concomitant to chemoradiation), then 7-9 days prior to surgery.
intervention_name	L-BLP25
intervention_type	Other
arm_group_label	Chemoradiation Therapy, L-BLP25
description	Radiotherapy (45-52 Gy) applied for five weeks. Oral capecitabine (825 mg/m² twice daily) or 5FU, started at the first day of radiotherapy and given 5-7 days per week during the time of radiotherapy.
intervention_name	Chemoradiation Therapy
intervention_type	Biological
arm_group_label	Chemoradiation Therapy, L-BLP25
description	L-BLP25 806 µg per vaccination once weekly for 8 weeks (concomitant to chemoradiation), then 7-9 days prior to surgery
intervention_name	L-BLP25
intervention_type	Other
arm_group_label	Chemoradiation Therapy
description	Radiotherapy (45-52 Gy) applied for five weeks. Oral capecitabine (825 mg/m² twice daily) or 5FU, started at the first day of radiotherapy and given 5-7 days per week during the time of radiotherapy.
intervention_name	Chemoradiation Therapy
Keywords:L-BLP25 (Stimuvax); Cyclophosphamide; Mode of action; Neoplasms; Neoplasms by Site; Carcinomas; Antineoplastic Agents,; Neoadjuvant; Radiotherapy Pharmacologic Actions; Immunosuppressive Agents; Immunologic Function; Therapeutic Uses; Molecular Mechanisms of Pharmacological Action
Lead sponsor: Industry; Merck KGaA
Intervention MeSH:Antineoplastic Agents; Cyclophosphamide; Immunosuppressive Agents; Molecular Mechanisms of Pharmacological Action
Condition MeSH:Rectal Neoplasms
### END TRIAL DATA ###

